Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.

By Pharmaceutical Processing | August 9, 2012

Bristol-Myers Squibb Company announced that yesterday it successfully completed the tender offer by Bristol-Myers Squibb Company through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. at a purchase price of $31.00 per share.

As of the expiration of the offer yesterday, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. As part of the successful completion of the tender offer, Bristol-Myers Squibb exercised its right granted under the merger agreement with Amylin pursuant to which the tender offer was made to purchase additional shares from Amylin which would allow Bristol-Myers Squibb to complete the merger without stockholder approval.

Also yesterday, Bristol-Myers Squibb acquired all of the remaining outstanding shares of Amylin common stock by means of a “short form merger” in which all such shares, other than shares held by Amylin in treasury or shares held by Amylin’s stockholders who are entitled to and have properly exercised appraisal rights under Delaware law, were converted into the right to receive $31.00 per share, in cash and without interest, less any applicable withholding taxes. Bristol-Myers Squibb intends to delist and de-register Amylin common stock as promptly as practicable following the effective time of the merger.

 

 

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE